Form 4: C4 Therapeutics Executive Kelly Schick Modifies Stock Option Holdings

Kelly Schick, Chief People Officer at C4 Therapeutics, adjusts stock option positions following an option repricing approved by the company's Compensation Committee.

Summary

• On March 8, 2024, a Form 4 filing was submitted to the SEC by Kelly Schick, Chief People Officer of C4 Therapeutics, Inc.
• The filing details changes in Ms. Schick's beneficial ownership of derivative securities, specifically stock options.
• On March 7, 2024, the Compensation Committee approved an option repricing, leading to adjustments in the number and exercise price of Ms. Schick's stock options.
• Ms. Schick disposed of options to buy 92,000 shares at $37.46 and acquired options to buy 92,000 shares at $19.
• She also disposed of options to buy 78,500 shares at $22.71 and acquired options to buy 78,500 shares at $19.
• The repricing did not alter other terms of the options, such as vesting schedules and expiration dates.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a transaction. The option repricing could be seen as a positive sign of the company's commitment to its employees, but it also suggests that the stock price may have underperformed, hence the middle-ground score.

Industry Context

Option repricing is a common practice in the biotech industry to incentivize employees, especially when the company's stock price has declined. It helps to keep employees motivated and aligned with the company's long-term goals.

Comparison to Industry Standards

• Option repricing is a fairly common practice, especially in volatile sectors like biotechnology.
• Many companies, such as Amgen, Gilead Sciences, and Biogen, have used similar strategies to retain and motivate key employees during periods of stock price underperformance.
• The specific terms of the repricing (e.g., the new exercise price, vesting schedules) would need to be compared against industry benchmarks to determine if they are competitive.

Stakeholder Impact

• Shareholders may view the option repricing as a positive sign of management's commitment to retaining talent.
• Employees, particularly Kelly Schick, benefit from the lower exercise price of the repriced options.
• The repricing could potentially dilute existing shareholders if the options are exercised in the future.

Key Dates